Accelerated Partial Breast Irradiation in One Fraction for Patients With Early-stage Disease and Favorable Histological Subtypes (Breast-1F).

Status: Recruiting
Location: See location...
Intervention Type: Radiation
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This is a prospective, randomized, monocentric, non-inferiority interventional clinical study comparing an Accelerated Partial Breast Irradiation (APBI) for the surgical bed of early-stage breast cancer patients with favorable histological subtypes, using stereotactic radiotherapy in a single dose of 15.5 Gy with Simultaneous Integrated Boost (SIB) to 21 Gy (study treatment, delivered in a single fraction) versus multifractionated radiotherapy of 30 Gy in 5 fractions (standard treatment, delivered in 5 fractions).

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 40
Healthy Volunteers: f
View:

• Histological diagnosis of breast cancer

• Patients aged ≥40 years

• Signed informed consent

• Stage pTis-T2, up to 3 cm in the greatest diameter

• Luminal A and Luminal B HER2-negative histological subtypes

• Negative surgical margins (≥ 0.2 cm)

• Negative lymph nodes at sentinel lymph node biopsy, or alternatively with imaging tests (Positron Emission Tomography (PET)/Computed Tomography (CT) and/or axillary ultrasound, and/or breast Magnetic Resonance Imaging (MRI) with and without contrast), or, in rare cases, where still performed, with axillary dissection

• Clinical M0 (PET/CT and/or bone scintigraphy and/or abdomen-pelvis CT with and without contrast in suspected patients), within the previous 3 months.

• Performance Status (PS) Eastern Cooperative Oncology Group (ECOG) ≤2

⁃ No prior thoracic radiotherapy

⁃ Fertile women using contraception methods initiated during oncological treatment.

Locations
Other Locations
Italy
IRCCS San Raffaele Scientific Institute
RECRUITING
Milan
Contact Information
Primary
Andrei Fodor, MD
fodor.andrei@hsr.it
+390226437634
Backup
Nadia G Di Muzio, Prof
dimuzio.nadia@hsr.it
+390226437643
Time Frame
Start Date: 2025-07-25
Estimated Completion Date: 2035-06-30
Participants
Target number of participants: 311
Treatments
Experimental: Arm 1- Single-fraction APBI
Patients in the study (randomized to arm 1) will be treated with a total dose (TD) of 15.5 Gy to the Planning Tumor Volume (PTV) with simultaneous integrated boost (SIB) to a TD of 21 Gy to the tumor bed. For each patient, a stereotactic radiotherapy treatment plan will be created to ensure adequate coverage of the treatment volumes and the tolerability of the Organs At Risk (OAR). Specific, already validated dose-volume constraints will be applied for the evaluation of OARs. The dose-volume histogram (DVH) for the Gross Tumor Volume (GTV), Clinical Target Volume (CTV), PTV, and OAR will be calculated in order to achieve the best optimization in terms of tolerability and efficacy.
Active_comparator: Arm 2- Five-fractions APBI
Patients randomized to arm 2 will be treated according to the standard APBI protocol of our department (Florence protocol), delivering a TD of 30 Gy in 5 fractions to the tumor bed.
Related Therapeutic Areas
Sponsors
Leads: IRCCS San Raffaele

This content was sourced from clinicaltrials.gov

Similar Clinical Trials